4 active not recruiting, 2 terminated, 1 completed, 1 withdrawn. 6 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 4, Terminated 1, Withdrawn 1 |
| Phase 1 | 4 | Active not recruiting 2, Completed 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow JDQ443: new trials by email Literature Review of JDQ443 trials Research Report on JDQ443
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| JDQ443 for KRAS G12C NSCLC Brain Metastases JDQ443 - Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult | Phase 2 | Withdrawn | Maastricht University Medical Center | 2024-04-15 | 2024-05-29 | |
| Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer JDQ443 - NSCLC | Phase 2 | Active not recruiting | Canadian Cancer Trials Group | 4 | 2023-09-15 | 2026-10-26 |
| Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. JDQ443 - Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 95 | 2022-12-06 | 2026-10-08 |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 74 | 2022-10-24 | 2026-10-21 |
| Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer JDQ443, docetaxel - Non-Small Cell Lung Cancer | Phase 3 | Terminated | Novartis Pharmaceuticals | 95 | 2022-06-15 | 2026-11-06 |
| A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. JDQ443 - Small Cell Lung Carcinoma | Phase 1 | Completed | Novartis Pharmaceuticals | 33 | 2022-05-03 | 2025-10-10 |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, TNO155, tislelizumab - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 344 | 2021-02-24 | 2026-10-19 |
Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Brain Neoplasms (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1)
Novartis Pharmaceuticals (6) · Canadian Cancer Trials Group (1) · Maastricht University Medical Center (1)
Italy (5) · Spain (5) · United States (5) · Belgium (4) · Canada (4) · China (4) · France (4) · South Korea (4) · Germany (3) · Malaysia (3) · Argentina (2) · Australia (2) · Denmark (2) · Greece (2) · Hong Kong (2)
Jonathan Spicer (1) · Lizza Hendriks, MD, PhD (1) · Normand Blais (1)
2023 (3), 2025 (1)